ストックスクリーナーアプリを入手
4.06
1.93%
-0.08
アフターアワーズ：
3.98
-0.08
-1.97%
前日終値:
$4.14
開ける：
$4.12
24時間の取引高:
546.93K
Relative Volume:
0.28
時価総額：
$289.02M
収益：
$26.87M
当期純損益:
$-137.06M
株価収益率:
-2.1275
EPS:
-1.9083
ネットキャッシュフロー:
$-125.25M
1週間 パフォーマンス:
+0.25%
1か月 パフォーマンス:
+5.73%
6か月 パフォーマンス:
+202.99%
1年 パフォーマンス:
+227.42%
1日の値動き範囲:
$4.00
$4.33
1週間の範囲:
$3.46
$4.33
52週間の値動き範囲:
$1.13
$6.95
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
名前
Zentalis Pharmaceuticals Inc
セクター
電話
(858) 263-4333
住所
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
4.06 | 294.71M | 26.87M | -137.06M | -125.25M | -1.9083 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-17 | 再開されました | Wells Fargo | Equal Weight |
| 2024-08-12 | アップグレード | Wedbush | Underperform → Neutral |
| 2024-06-20 | ダウングレード | UBS | Buy → Neutral |
| 2024-06-18 | ダウングレード | Jefferies | Buy → Hold |
| 2024-06-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-18 | ダウングレード | Wedbush | Neutral → Underperform |
| 2024-06-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-08 | ダウングレード | Wedbush | Outperform → Neutral |
| 2023-11-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2022-07-12 | 開始されました | Cowen | Outperform |
| 2022-04-06 | 開始されました | Wells Fargo | Overweight |
| 2021-10-07 | 再開されました | Jefferies | Buy |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-09-29 | 開始されました | Oppenheimer | Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-01-20 | 開始されました | Wedbush | Outperform |
| 2020-09-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-28 | 開始されました | Guggenheim | Buy |
| 2020-04-28 | 開始されました | Jefferies | Buy |
| 2020-04-28 | 開始されました | Morgan Stanley | Overweight |
| 2020-04-28 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Zentalis Pharmaceuticals Inc (ZNTL) 最新ニュース
Zendesk Inc (ZEN) - Minichart
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial - GlobeNewswire
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - Yahoo Finance
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
What's behind the surge in Zentalis stock? - MSN
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.5, Implies 52% Upside - TradingView
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts - TipRanks
Zentalis Pharmaceuticals 1Q Loss/Shr 50c >ZNTL - Moomoo
TradingKey - TradingKey
Is Zentalis Pharmaceuticals (ZNTL) Attractive After Q1 2026 Earn - GuruFocus
ZNTL Advances Key Trials for Ovarian Cancer Treatment - GuruFocus
ZNTL: Azenosertib shows >30% ORR in Cyclin E1-positive PROC, targeting a major unmet need - TradingView
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zentalis Advances Azenosertib with New Trial Updates - TipRanks
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - The Manila Times
Zentalis (ZNTL) trims Q1 loss as azenosertib moves into Phase 3 - Stock Titan
Zentalis Pharmaceuticals, Inc. 1Q 2026: Net income $(35.4)M, EPS $(0.50) — 10-Q Summary - TradingView
Zentalis (Nasdaq: ZNTL) trims Q1 2026 loss while pushing azenosertib toward pivotal ovarian cancer milestones - Stock Titan
Press Release: Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - Moomoo
Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com South Africa
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
Zentalis Pharmaceuticals Inc (ZNTL) 財務データ
収益
当期純利益
現金流量
EPS
2.98%
1.33%
大文字化:
|
ボリューム (24 時間):